Iterum Therapeutics (ITRM) Competitors $1.26 -0.03 (-2.33%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.40%) As of 03/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. CKPT, LFVN, NMRA, CRGX, AMRN, TNGX, OCGN, KOD, CGC, and ACRSShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Checkpoint Therapeutics (CKPT), LifeVantage (LFVN), Neumora Therapeutics (NMRA), CARGO Therapeutics (CRGX), Amarin (AMRN), Tango Therapeutics (TNGX), Ocugen (OCGN), Kodiak Sciences (KOD), Canopy Growth (CGC), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Checkpoint Therapeutics LifeVantage Neumora Therapeutics CARGO Therapeutics Amarin Tango Therapeutics Ocugen Kodiak Sciences Canopy Growth Aclaris Therapeutics Checkpoint Therapeutics (NASDAQ:CKPT) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Which has more risk & volatility, CKPT or ITRM? Checkpoint Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Which has preferable earnings & valuation, CKPT or ITRM? Iterum Therapeutics has lower revenue, but higher earnings than Checkpoint Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$47K4,197.56-$51.85M-$1.84-2.20Iterum TherapeuticsN/AN/A-$24.77M-$1.31-0.96 Does the MarketBeat Community prefer CKPT or ITRM? Checkpoint Therapeutics received 40 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 67.04% of users gave Checkpoint Therapeutics an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18167.04% Underperform Votes8932.96% Iterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Does the media favor CKPT or ITRM? In the previous week, Checkpoint Therapeutics had 5 more articles in the media than Iterum Therapeutics. MarketBeat recorded 6 mentions for Checkpoint Therapeutics and 1 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 1.87 beat Checkpoint Therapeutics' score of 0.08 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Checkpoint Therapeutics Neutral Iterum Therapeutics Very Positive Is CKPT or ITRM more profitable? Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Iterum Therapeutics N/A N/A -90.85% Do insiders and institutionals hold more shares of CKPT or ITRM? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend CKPT or ITRM? Checkpoint Therapeutics presently has a consensus price target of $4.33, indicating a potential upside of 7.26%. Iterum Therapeutics has a consensus price target of $5.00, indicating a potential upside of 296.83%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryIterum Therapeutics beats Checkpoint Therapeutics on 9 of the 14 factors compared between the two stocks. Remove Ads Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.57M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.967.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book-10.506.386.894.23Net Income-$24.77M$142.34M$3.20B$247.47M7 Day Performance-12.50%-5.15%-3.06%-2.29%1 Month Performance-9.68%-7.55%1.52%-5.81%1 Year Performance-18.18%-11.06%9.37%-0.96% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.0763 of 5 stars$1.26-2.3%$5.00+296.8%-18.2%$43.57MN/A-0.9610Positive NewsGap UpCKPTCheckpoint Therapeutics2.204 of 5 stars$4.05-0.5%$4.33+7.0%+97.1%$197.77M$47,000.00-2.2010Earnings ReportShort Interest ↓News CoverageLFVNLifeVantage3.7847 of 5 stars$15.56+0.6%$30.50+96.0%+138.3%$195.29M$212.15M27.79260Positive NewsNMRANeumora Therapeutics3.1869 of 5 stars$1.20+6.2%$10.14+745.2%-92.5%$194.38MN/A-0.64108CRGXCARGO Therapeutics3.1382 of 5 stars$4.20+0.5%$15.00+257.1%-81.3%$193.42MN/A-0.99116Analyst RevisionGap UpAMRNAmarin0.9781 of 5 stars$0.46+1.6%N/A-50.6%$190.76M$228.61M-5.16360Short Interest ↓Positive NewsTNGXTango Therapeutics1.7982 of 5 stars$1.74-1.1%$12.33+608.8%-81.5%$188.11M$42.07M-1.4790Short Interest ↑OCGNOcugen1.2923 of 5 stars$0.64+5.4%$6.33+893.6%-51.3%$186.13M$4.06M-3.5480Analyst RevisionPositive NewsKODKodiak Sciences3.9967 of 5 stars$3.52+7.3%$8.00+127.3%-44.7%$185.24MN/A-0.9690Earnings ReportNews CoverageCGCCanopy Growth2.3997 of 5 stars$1.16+4.5%$2.00+72.4%-88.6%$183.99M$276.75M-0.313,150Positive NewsACRSAclaris Therapeutics2.2391 of 5 stars$1.70+6.3%$11.67+586.3%+28.2%$183.46M$18.72M-3.27100Short Interest ↑ Remove Ads Related Companies and Tools Related Companies Checkpoint Therapeutics Alternatives LifeVantage Alternatives Neumora Therapeutics Alternatives CARGO Therapeutics Alternatives Amarin Alternatives Tango Therapeutics Alternatives Ocugen Alternatives Kodiak Sciences Alternatives Canopy Growth Alternatives Aclaris Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITRM Stock Free ITRM Stock Alerts